Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 3, 2008, Pages 298-308

  Jacobson, Denise L ^a,d   Spiegelman, Donna ^a   Knox, Tamsin K ^b   Wilson, Ira B ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

Author keywords

Antiretroviral therapy; BMI; Bone mineral density; Exercise; HIV; Longitudinal; Menopause

Indexed keywords

ALBUMIN; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; HYDROCORTISONE; PREDNISONE; SAQUINAVIR; STAVUDINE; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; BODY WEIGHT; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CIGARETTE SMOKING; DIET; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EVOLUTION; FEMALE; HEALTH BEHAVIOR; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUTRITION; OSTEOLYSIS; OSTEOPENIA; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RACE; SEX; SMOKING; STRENGTH; TRAINING; TREATMENT DURATION; VIROTHERAPY; VIRUS LOAD; COHORT ANALYSIS; LONGITUDINAL STUDY; MENOPAUSE; METABOLISM; MIDDLE AGED; PHOTON ABSORPTIOMETRY; TIME;

ABSORPTIOMETRY, PHOTON; ADULT; ANTI-HIV AGENTS; BONE DENSITY; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MENOPAUSE; MIDDLE AGED; TIME FACTORS;

EID: 58149155951     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181893e8e     Document Type: Article

References (59)

1. Glesby MJ. Bone disorders in human immunodeficiency virus infection. Clin Infect Dis. 2003;37:S91-S95.
2. Thomas J, Doherty SM. HIV infection-a risk factor for osteoporosis. J Acquir Immune Defic Syndr. 2003;33:281-291.
3. Fairfield WP, Finkelstein JS, Klibanski A, et al. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. J Clin Endocrinol Metab. 2001;86:2020-2026.
4. Moore AL, Vashisht A, Sabin CA, et al. Reduced bone mineral density in HIV-positive individuals. AIDS. 2001;15:1731-1733.
5. Knobel H, Guelar A, Vallecillo G, et al. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS. 2001;15:807-808.
6. Loiseau-Peres S, Delaunay C, Poupon S, et al. Osteopenia in patients infected by the human immunodeficiency virus. A case control suidy. Joint Bone Spine. 2002;69:482-485.
7. Amsten JH, Freeman R, Howard AA, et al. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis. 2006;42:10141020.
8. Brown TT, Ruppe MD, Kassner R, et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab. 2004;89:1200-1206.
9. Carr A, Miller J, Eisman JA, et al. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight preantiretroviral therapy. AIDS. 2001;15:703-709.
10. Huang JS, Wilkie SJ, Sullivan MP, et al. Reduced bone density in androgen deficient women with acquired immune deficiency syndrome wasting. J Clin Endocrinol Metab. 2001;86:3533-3539.
11. Huang JS, Rietschel P, Hadigan CM, et al. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS. 2001;15:975-982.
12. McDermott AY, Shevitz A, Knox T, et al. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr. 2001;74:679-686.
13. Nolan D, Upton R, McKinnon E, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS. 2001;15:1275-1280.
14. Tebas P, Yarasheski K, Henry K, et al. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses. 2004;20:589-594.
15. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482-490.
16. Tsekes G, Chrysos G. Douskas G, et al. Body composition changes in protease inhibitor-naive HIV-infected patients with two nucleoside reverse transcriptase inhibitors. HIV Med. 2002;3:85-90.
17. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in HIV-infected women. J Clin Endocrinol Metab. 2006;91:2938-2945.
18. McDermott AY, Terrin N, Wanke C, et al. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clin Infect Dis. 2005;41:1662-1670.
19. Van Rompay KKA, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy) propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother. 2004;48:1469-1487.
20. Castillo AB. Tarantal AF. Watnik MR, et al. Tenofovir treatment at 30 mg/ kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (macaca mulatta). J Orthop Res. 2002;20:1185-1189,
21. Gallant JE. Staszewski S, Pozniak AI, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. JAMA. 2004;292:191-201.
22. Guest JL, Rimland D, Patterson BY, et al. Tenofovir-induced nephrotoxicity in the first year of therapy. Paper presented at: Conference on Retroviruses and Opportunistic Infections; 2006; Denver, CO.
23. Shevitz AH, Knox TA, Spiegelman D, et al. Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. AIDS. 1999;13:1351-1357.
24. Silva M, Skolnik PR, Gorbach SL, et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS. 1998;12: 1645-1651.
25. Wilson IB, Roubenoff R, Knox TA, et al. Relation of lean body mass to health-related quality of life in persons with HIV J Acquir Immune Defic Syndr. 2000;24:137-146.
26. Forrester JE, Spiegelman D, Tchetgen E, et al. Weight loss and bodycomposition changes in men and women infected with HIV Am J Clin Nutr. 2002;76:1428-1434.
27. Knox TA, Spiegelman D, Skinner SC, et al. Diarrhea and abnormalities of gastrointestinal function in a cohort of men and women with HIV infection. Am J Gastroenterol. 2000;95:3482-3489.
28. Jacobson DL, Knox TA, Spiegelman D, et al. Prevalence, evolution and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis. 2005;40:1837-1845.
29. Federal Register. Annual Update of the HHSPovertv Guidelines. 1998;63: 9235-9238.
30. Sallis JF, Haskell WL, Wood PD, et al. Physical activity assessment methodology in the five-city project. Am J Epidemiol. 1985;121:91-106.
31. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8:551-561.
32. Nguyen TV, Maynard LM, Towne B, et al. Sex differences in bone mass acquisition during growth: the fels longitudinal study. J Clin Densitom. 2001;4:147-157.
33. Riggs BL, Melton LJ. Osteopomsis: Etiology, Diagnosis and Management. Vol 2. Philadelphia, PA: Lippincott-Raven; 1995.
34. Favus MJ, ed. Primer on the Metabolic Bone Disorders and Disorders of Mineral Metabolism. 5th ed. Washington, DC: American Society for Bone and Mineral Research; 2003.
35. Cooper C. Epidemiology of osteoporosis. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineml Metabolism. Vol 5. Washington, DC: American Society for Bone and Mineral Research; 2003:311.
36. Bolland MJ, Grey AB, Gamble GD, et al. Clinical review: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab. 2007;92: 4522-4528.
37. Chumlea WC, Wisemandle W, Guo SS, et al. Relations between frame size and body composition and bone mineral status. Am J Clin Nutr. 2002; 75:1012-1016.
38. Bakker I, Twisk JW, Van Mechelen W, et al. Fat-free body mass is the most important body composition determinant of 10-yr longitudinal development of lumbar bone in adult men and women. J Clin Endocrinol Metab. 2003;88:2607-2613.
39. Wanke CA, Silva M, Knox TA, et al. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Inject Dis. 2000;31:803-805.
40. Tang AM, Jacobson DL, Spiegelman D, et al. Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003. J Acquir Immune Defic Syndr. 2005;40:70-76.
41. Lawal A, Engelson ES, Wang J, et al. Equivalent osteopenia in HIVinfected individuals studied before and during the era of highly active antiretroviral therapy. AIDS. 2001;15:278-280.
42. Driscoll SD, Meininger GE, Lareau MT, et al. Effects of exercise training and metformin on body composition and cardiovascular indices in HIVinfected patients. AIDS. 2004;18:465-473.
43. Shevitz AH, Wilson IB, McDermott AY. et al. A comparison of the clinical and cost-effectiveness of 3 intervention strategies for AIDS wasting. J Acquir Immune Defic Syndr. 2005;38:399-406.
44. Dolan SE, Frontera W, Librizzi J, et al. Effects of a supervised home- based aerobic and progressive resistance training regimen in women infected with human immunodeficiency virus: a randomized trial. Arch Intern Med. 2006;166:1225-1231.
45. Perez-Moreno F, Camara-Sanchez M, Tremblay JF, et al. Benefits of exercise training in Spanish prison inmates. Int J Sports Med. 2007.
46. Roubenoff R, Wilson IB. Effect of resistance training on self-reported physical functioning in HIV infection. Med Sci Sports Exerc. 2001;33: 1811-1817.
47. Fillipas S, Oldmeadow LB, Bailey MJ, et al. A six-month, supervised, aerobic and resistance exercise program improves self-efficacy in people with human immunodeficiency virus: a randomised controlled trial. Aust J Physiother. 2006;52:185-190.
48. Driscoll SD, Meininger GE, Ljungquist K, et al. Differential effects of metformin and exercise on muscle adiposity and metabolic indices in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab. 2004;89:2171-2178.
49. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxy vitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18-28.
50. Fernandez-Rivera J, Garcia R, Lozano F, et al. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. Hiv Clin Trials. 2003;4: 337-346.
51. Melchior JC, Niyongabo T, Henzel D, et al. Malnutrition and wasting, immunodepression, and chronic inflammation as independent predictors of survival in HIV-infected patients. Nutrition. 1999;15:865-869.
52. Brechtl JR, Patrick PA, Visintainer P, et al. Predictors of death within six months in patients with advanced AIDS. Paillat Support Care. 2005;3: 265-272.
53. Olawumi HO, Olatunji PO. The value of serum, albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients. HTV Med. 2006;7:351-355.
54. Mehta SH, Astemborski J, Sterling TR, et al. Serum, albumin as a prognostic indicator for HIV disease progression. AIDS Res Hum Retroviruses. 2006;22:14-21.
55. Bonarek M, Morlat P, Chene G, et al. Prognostic score of short-term survival in HIV-infected patients admitted to medical intensive care units. Int J STD AIDS. 2001;12:239-244.
56. Afessa B, Green B. Clinical course, prognostic factors, and outcome prediction for HIV patients in the ICU. The PIP (pulmonary complications, ICU support, and prognostic factors in hospitalized patients with HIV) study. Chest. 2000;118:138-145.
57. Blake GM, Fogelman I. The role of bone density measurements in the evaluation of new treatments for osteoporosis. Curr Pharm Des. 2002;8:1885-1905.
58. Blake GM, Herd RJ, Patel R, et al. The effect of weight change on total body dual-energy X-ray absorptiometry: results from a clinical trial. Osteoporos Int. 2000;11:832-839.
59. Blake GM., Knapp KM, Spector TD, et al. Predicting the risk of fracture at any site in the skeleton: are all bone mineral density measurement sites equally effective? Calc if Tissue Int. 2006;78:9-17.